Growth hormone releasing peptide-6 (GHRP-6)
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Research / no approved-treatment claim
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Purported uses, not established benefits
Proponents claim GHRP-6 may stimulate growth-hormone release, increase appetite and improve muscle-to-fat body composition.
The review distinguishes endocrine responses from limited direct evidence of meaningful body-composition benefit.
Evidence and source limits
Compounded drugs containing GHRP-6 may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has identified limited safety-related information, but the available data reveal safety concerns including potential effect on cortisol and increase in blood glucose due to decreases in insulin sensitivity.
This entry records a regulator safety assessment, not a treatment benefit or a clinical recommendation. A research-purpose-only label does not establish safety, FDA approval or permission to use a substance in people. No dosing, supplier or administration guidance is provided.
Original source: Growth hormone releasing peptide-6 (GHRP-6) ↗
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.